Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

    Celgene Reports Positive Data on Dermatology Drug Otezla

    Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.

      FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

      FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

        Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

        Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.

          Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

          Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.

            The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

            The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

              Sanghamitra Saha headshot

              Biotech ETF (XBI) Hits New 52-Week High

              This biotech ETF hit a new 52-week high. Are more gains in store for this fund?

                Company News For Jan 26, 2018

                Companies in the news are: CELG,FCX,EGHT,ALK

                  Infinity Provides Update on Lead Candidate, Issues 2018 View

                  Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.

                    Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

                    J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

                      Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

                      Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.

                        Ekta Bagri headshot

                        Celgene (CELG) Beats on Q4 Earnings

                        Celgene topped earnings expectations in the fourth quarter of 2017. The company also surpassed sales estimates.

                          Tirthankar Chakraborty headshot

                          Play Biotech Buyout Frenzy With These 2 Solid Funds

                          More deals are expected to be signed in the biotech space, courtesy of the tax reform bill that allows companies to repatriate cash piled overseas

                            Stock Market News For Jan 23, 2018

                            Major benchmarks hit record highs on Monday after the Senate gave its consent to pass a Bill that ends the current government shutdown.

                              Bluebird Up on Buyout Speculation After Celgene/Juno Deal

                              Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.

                                Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

                                Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.

                                  Sweta Killa headshot

                                  Biotech ETF (BBC) Hits New 52-Week High

                                  This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

                                    Tirthankar Chakraborty headshot

                                    Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

                                    More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.

                                      The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck

                                      The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck

                                        Arpita Dutt headshot

                                        Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?

                                        Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?

                                          Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?

                                          Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.

                                            Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

                                            Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

                                              Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?

                                              J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.

                                                Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

                                                Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.

                                                  Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label

                                                  Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.